Ascentage Pharma Group International (NASDAQ:AAPG) Earns Buy Rating from BTIG Research

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $48.00 price objective on the stock. BTIG Research‘s price objective suggests a potential upside of 261.17% from the stock’s current price.

Several other research firms have also recently weighed in on AAPG. Citigroup initiated coverage on shares of Ascentage Pharma Group International in a research report on Wednesday, October 14th. They issued a “buy” rating and a $46.00 price objective for the company. William Blair assumed coverage on shares of Ascentage Pharma Group International in a research report on Friday, October 16th. They set an “outperform” rating on the stock. JPMorgan Chase & Co. decreased their price target on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating on the stock in a research note on Thursday, October 8th. Finally, Citizens Jmp assumed coverage on shares of Ascentage Pharma Group International in a report on Tuesday, October 13th. They issued a “market outperform” rating and a $35.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating and eleven have assigned a Buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $43.44.

View Our Latest Research Report on AAPG

Ascentage Pharma Group International Stock Down 9.1%

Ascentage Pharma Group International stock opened at $13.29 on Tuesday. The stock has a 50-day simple moving average of $15.28 and a 200 day simple moving average of $19.55. The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. Ascentage Pharma Group International has a 12-month low of $13.25 and a 12-month high of $33.09.

Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last issued its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million for the quarter. On average, equities research analysts predict that Ascentage Pharma Group International will post -2.43 earnings per share for the current fiscal year.

Ascentage Pharma Group International Company Profile

(Get Free Report)

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Featured Stories

Analyst Recommendations for Ascentage Pharma Group International (NASDAQ:AAPG)

Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.